Novel antibiotic with the potential to be the first oral carbapenem for use in adults to treat complicated urinary tract infection and acute pyelonephritis.
Novel agent with the potential to be the first oral antibiotic specifically approved for the treatment of NTM disease.
Learn about the investment opportunity, see our upcoming events and download our latest corporate presentation.
Investment opportunities >Join a passionate team that pushes the limits in finding innovative therapies to help patients.
Career opportunities >Our strategic partnerships foster mutually beneficial alliances that advance medicine to improve patient lives.
Partnership opportunities >